Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 monthsCHICAGO, USA and OXFORD, UK October 20th 2025 – ...

Successful inspections maintain 19 years of quality and transparency ~Contract research organisation and scientific consultancy Broughton has successfully hosted inspections by the United Kingdom ...